FDA Launches Global Reliance Disclosure Program and Approves First Drug Extending Survival in Infantile-Onset Niemann-Pick Disease Type C as WHO and 21 Countries Pledge 5% Obesity Reduction by 2030
On November 17, the U.S. FDA launched the Global Reliance Disclosure Program to share minimally redacted drug review packages with foreign regulators and approved Lembaz to reduce mortality by 55% in infantile-onset Niemann-Pick disease type C, while WHO, UNICEF, Spain, and 20 frontrunner countries committed to cut obesity prevalence by 5% by 2030.
By 全球伯乐 News
Source compilation
On this page
On November 17, the U.S. Food and Drug Administration (FDA) announced two major regulatory actions: launching the Global Reliance Disclosure Program (GRDP) to share minimally redacted scientific assessment packages with foreign health authorities within days of U.S. approval1, and approving Lembaz (adrabetadex) injection as the first therapy shown to extend survival in infantile-onset Niemann-Pick disease type C (NPC) with a 55% reduction in the risk of death2. On the same day, the World Health Organization (WHO), UNICEF, the Government of Spain, and 20 acceleration-plan frontrunner countries including European Union members Ireland, Portugal, and Slovenia launched the "Bending the curve by 2030" global call to action on obesity, committing to reduce national and childhood obesity prevalence by 5% by 20303.

AI-generated editorial illustration: a sealed borosilicate glass medicinal ampoule containing pale amber liquid, an unbranded silver anodized cold-chain cylinder, and a white porcelain bowl holding a translucent glass bead on a frosted architectural glass block symbolize cross-border regulatory reliance, rare-disease intrathecal therapy breakthroughs, and global obesity prevention alliances, not an actual clinical or regulatory photograph.
FDA Global Reliance Disclosure Program Expedites Unredacted Review Sharing and Expands to All Novel Drugs in January 2027
According to the FDA press announcement on the Global Reliance Disclosure Program, patients in lower-resource countries frequently wait months or years after an FDA approval while national authorities conduct duplicative independent reviews under capacity constraints1. Under the GRDP, pharmaceutical sponsors can request minimally redacted approval packages containing the FDA detailed scientific and regulatory assessments within 10 calendar days of approval and transmit them directly to foreign regulatory agencies, enabling partner regulators to rely on FDA findings while retaining full sovereign decision-making authority1.
The program debuted on October 30, 2026 with a President Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir for HIV prevention and treatment, and currently covers PEPFAR tentative approvals excluding abbreviated new drug applications (ANDAs)1. FDA Deputy Commissioner Grace Graham and Associate Commissioner Mark Abdoo confirmed that in January 2027 the agency will expand the GRDP to all novel drugs and biologics—covering New Molecular Entity New Drug Applications (NME NDAs) and 351(a) Biologics License Applications (BLAs)—and will introduce a dedicated pathway in early 2027 for already-marketed FDA-approved products, while non-regulatory disclosure requests remain governed by Freedom of Information Act (FOIA) procedures1.
Intrathecal Lembaz Reduces Mortality Risk by 55% and Extends Median Survival to 8.5 Years in Infantile-Onset NPC
In a parallel rare-disease milestone, the FDA issued its approval announcement for Lembaz (adrabetadex) injection, granting marketing authorization to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC, for adult and pediatric patients weighing at least 7 kg (about 15 pounds) with Niemann-Pick disease type C whose neurological symptoms began before age 62. Affecting roughly 1 in 150,000 people, NPC is an inherited lysosomal storage disorder in which impaired intracellular cholesterol and lipid transport causes progressive neurological deterioration; whereas two previously approved NPC therapies carried age and weight restrictions and lacked demonstrated survival benefits, Lembaz is administered every two weeks via intrathecal injection into the spinal canal to directly target neurological decline2.
The FDA evaluated overall survival across 36 patients with infantile-onset NPC treated with Lembaz across three clinical studies and an expanded access program compared against a matched external control group2. Treated patients achieved a 55% reduction in the risk of death and a median survival time of 8.5 years compared with 4.9 years in the control group, regardless of concomitant off-label miglustat use2. Because Lembaz carries a boxed warning for hearing impairment—including permanent hearing loss—alongside potential balance disturbances, fatigue, and vomiting, the prescribing information mandates comprehensive baseline and regular follow-up audiological evaluations with corresponding dose adjustments2.
Spain and 20 Frontrunner Countries Join WHO and UNICEF to Cut Obesity Prevalence by 5% by 2030
Addressing chronic metabolic disease on the same day, the World Health Organization and UNICEF joined Spain and 20 frontrunner governments—Bahrain, Barbados, Botswana, Brazil, Brunei Darussalam, Egypt, Eswatini, Ireland, Jordan, Malaysia, Mauritius, Mexico, Panama, the Philippines, Portugal, Seychelles, Slovenia, South Africa, Thailand, and Uruguay—to launch the "Bending the curve by 2030" call to action on obesity3. WHO reported that more than 1 billion people globally (1 in 7 worldwide) now live with obesity; prevalence has more than doubled in adults and quadrupled in adolescents since 1990, and in 2025 obesity overtook underweight for the first time as the most common form of malnutrition among children and adolescents aged 5 to 19 years3.
WHO Director-General Dr. Tedros Adhanom Ghebreyesus and Spanish Health Minister Monica Garcia Gomez emphasized that participating countries have pledged to reduce national and childhood obesity prevalence by 5% by 2030 through coordinated population-level prevention, earlier risk identification, and accessible primary-care management3. Recommended interventions from the WHO acceleration plan and NCD Best Buys include breastfeeding and complementary feeding support, healthy school nutrition standards, taxes on sugar-sweetened beverages, mandatory front-of-pack nutrition labeling, restrictions on marketing unhealthy foods to children, and integrating pharmacotherapy and patient co-design into primary healthcare pathways3.
Source notes
-
2026-11-17 · FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide · U.S. Food and Drug Administration (FDA). ↩ ↩2 ↩3 ↩4 ↩5
-
2026-11-17 · FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer · U.S. Food and Drug Administration (FDA). ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
2026-11-17 · Leaders commit to accelerate action on obesity prevention and control · World Health Organization (WHO). ↩ ↩2 ↩3 ↩4 ↩5


